What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3, Pre-Registered Trial).

December 8, 2025Blood

Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study

View Full Paper

Ask AI

Bookmark

Authors

SSSuthesh Sivapalaratnam RSRoger E. G. SchutgensUtrecht University JZJenny Y. ZhouUniversity of San Diego

Discussion

Member takes

Implication

Interim Phase 2 results find sutacimig reduces annual bleeding rate by over 50% in glanzmann thrombasthenia, suggesting promising efficacy and safety.

Key Points

Sutacimig achieved over 50% reduction in median annualized treated bleeding rate in glanzmann thrombasthenia patients during Phase 2.
Interim analysis shows satisfactory safety profile with 82% adverse events mostly mild to moderate among 34 participants.
Assessment using multicenter, open-label methodology to evaluate prophylactic subcutaneous sutacimig in different dosages.
Findings support further research into prophylactic therapy for glanzmann thrombasthenia; Phase 3 trial planning is underway.

Cite This Study

Sivapalaratnam et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e340 https://doi.org/10.1182/blood-2025-842

View Full Paper

Ask AI

Bookmark

Implication

Interim Phase 2 results find sutacimig reduces annual bleeding rate by over 50% in glanzmann thrombasthenia, suggesting promising efficacy and safety.

Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider